Intelligence:

Whitepaper

Home / Intelligence / Whitepaper

Search

The 2020 Dichotomy: An Analysis of the COVID-19 Launch Class and How Commercial Innovation Failed…

Despite the challenges the COVID-19 pandemic created, 2020 was an exceptional year for the biopharma industry. The race to develop effective treatments and vaccines for COVID elevated the public’s perception of biotechnology, and, for many, the industry provided a source of hope during the pandemic. As early-stage venture capitalist Bruce Booth observed in his review of 2020, investors’ enthusiasm sent biotech indexes to all-time highs, boosted the performance of IPOs and accelerated venture capital funding. The NASDAQ Biotech Index finished…

Read Now

How Monoclonal Antibodies Can Help in the Fight Against the COVID-19 Pandemic

In this article, we aim to explain how monoclonal antibodies can help in the fight against the COVID-19 pandemic. While there are still unknowns about these drugs – such as their real-life efficacy and long-term effects, amongst others –antibodies nonetheless have the potential to effectively target several stages of the disease with evident benefits at a patient level (by alleviating symptoms and preventing progression to severe disease) and at a systemic level (by reducing the strain on the overburdened health…

Read Now

Launching During COVID-19 Whitepaper

What is and isn’t working for drug launches amid COVID-19? Six months after COVID-19 lock-downs began, Trinity has uncovered some surprising (and some concerning) answers to key questions everyone is asking. In this paper, we examine the trajectory of new molecular entities (NMEs) approved in late 2019 and early 2020 to understand how to drive a successful drug launch (and avoid the pitfalls) in the age of COVID-19.…

Read Now

Launching During COVID-19

What is and isn’t working for drug launches amid COVID-19? Six months after COVID-19 lock-down began, Trinity has uncovered some surprising (and some concerning) answers to key questions everyone is asking. In this paper, we examine the trajectory of new molecular entities (NMEs) approved in late 2019 and early 2020 to understand how to drive a successful launch (and avoid the pitfalls) in the age of COVID-19. Please complete the form to download a copy of our Launching During COVID-19…

Read Now

Achieving Launch Excellence in this New Decade: Four Must-Haves for an Agile Launch Strategy

2018 and 2019 were banner years for approvals with over 50 drugs approved by the FDA and the EMA each year. 2020 looks no different. As you prepare for your unique launch in an ever-changing landscape, we understand the challenges you may face: limited resources, lack of prioritization, misalignment, diversity of markets. Based on Trinity’s experience supporting dozens of launches in 2019 alone and through a landmark research study with 30 Chief Commercial Officers (CCOs) who had recently launched a product, we…

Read Now

Spending Wisely in Europe

By 2022 Europe is forecast to account for 20% of a global US$1.2 trillion pharmaceutical market. For executives from emerging biopharmaceutical companies planning to develop and commercialize their assets in Europe, the views of biopharmaceutical investors are critical, as investors provide the necessary investments. Additionally, investors who have analyzed numerous biopharmaceutical companies will have valuable experience on what drives commercial success. In this paper, we aim to understand the views of both investors and biopharmaceutical companies, specifically on the investments…

Read Now

Commercializing Cell and Gene Therapies: Overcoming the Barriers to Commercial Success

Cell and Gene Therapy (CGT) is an exciting new frontier in the biopharmaceutical industry. The novelty of the technology and market introduces many complexities for companies commercializing CGTs. This white paper analyzes the challenges faced and outlines six key questions to consider for reducing complexity and supporting commercial success: Are we confident in the supply chain right up until administration of the treatment to the patient? Do we have the right pricing, reimbursement, and evidence model in place, not just…

Read Now

How Five Oncology Treatment Paradigms Determine Strategic Choices for Commercial Success

New targeted oncology treatment regimens have changed cancer treatment. This white paper charts that development and analyzes five different approaches, providing an overview of how these paradigms determine strategic choices for commercial success. We observe that: The oncology treatment landscape has five distinct treatment paradigms.Competition, routes of administration, and market dynamics differ dramatically for each paradigm.The approach to commercialization needs to differ for each paradigm to increase uptake and ensure successful market penetration. Download the White Paper…

Read Now

Exploring the Truth of Reimbursement Challenges for Cell and Gene Therapies

Trinity has worked with over a third of companies with cell and gene therapies (CGTs) on market or in Phase 3 clinical trials. Our work has supported business development, launch planning, evidence generation (HEOR, etc.), market access, pricing, and other critical commercial activities to support the development and launch of these therapies. As such, we have seen CGTs morph from a small niche into possibly the most exciting market in pharma. 2019 is poised to be an inflection point for…

Read Now

Trinity Drug Index

The annual Trinity Drug Index provides a comprehensive evaluation of the performance of drugs by therapeutic value, commercial performance and R&D complexity.…

Read Now